bioAffinity Technologies Closes $4 Million Registered Direct Offering to Support CyPath® Lung Sales and Corporate Operations bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for…
Corcym Reports Positive Seven-Year Mid-Term Data for Perceval Plus Sutureless Aortic Valve in MANTRA Clinical Study Corcym, a global medical device company focused on cardiac surgery, has announced positive mid-term…
Affinia Therapeutics to Present AFTX-201 Preclinical Data and UPBEAT Trial Progress in BAG3-Associated Dilated Cardiomyopathy at HFSA 2026 Affinia Therapeutics, a clinical-stage gene therapy company developing potentially first-in-class and best-in-class…
Secretome Therapeutics to Present Phase 1 Clinical Data for STM-01 in Heart Failure With Preserved Ejection Fraction Secretome Therapeutics, a clinical-stage biotechnology company developing innovative therapies derived from neonatal cardiac…
Glaukos Reports Positive Phase 4 Results for iDose TR Combined With Cataract Surgery in Glaucoma Patients Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative treatments…
Seaport Therapeutics Presents Phase 1 Clinical Data Showing Improved Bioavailability and Reduced Pharmacokinetic Variability for GlyphAgo Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage therapeutics company focused on developing innovative medicines…
Ascensia Diabetes Care Partners with Sava Technologies to Advance Wearable Microsensor Technology for Glucose Monitoring Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (Tokyo…
Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S.…
INBRAIN Neuroelectronics Completes MINIGRAPH Project, Advancing Graphene-Based Brain-Computer Interfaces and Robotic Neural Implantation INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing graphene-based brain-computer interface (BCI) therapeutics, has announced the successful completion…
Glaukos Reports Positive Three-Year Phase 3 Extension Results for Epioxa in Keratoconus Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative therapies for glaucoma, corneal disorders…
Life Sciences BC Selects 2027 Investor Readiness Program Cohort to Support Growth of Emerging Life Sciences Companies Life Sciences BC (LSBC) has announced the companies selected to participate in its…
PureTech’s Seaport Therapeutics Doses First Patient in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder PureTech Health plc (LSE: PRTC) announced that its Founded Entity, Seaport Therapeutics (Nasdaq: SPTX),…